IP Library Granted Patent US 8,263,384
Granted Patent B2
US 8,263,384 · App. 12/278,227 · Granted Sep 11, 2012

Biological production of thymidine

Assignee: Glaxo Group Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,263,384
App. No.
12/278,227
Granted
Sep 11, 2012
Kind
B2
Abstract

Novel organisms, including DNA construct host cell combinations, are disclosed. The organisms comprise a transcription unit (e.g. operon) comprising DNA sequences encoding for enzymes which promote the supply of single carbon units for the conversion of dUMP to dTMP. Examples include: dihydrofolate reductase genes e.g. T4 frd; Serine Hydroxymethyltransferase genes e.g. glyA; 3-phosphoglycerate dehydrogenase genes e.g. serA; and THF synthase genes e.g. ADE3. The organisms are used in a biological method of producing thymidine with significantly reduced levels of uridine.

Claims (6)

1. A bacterium capable of producing thymidine when grown in a culture medium, the bacterium comprising one or more genetic modifications to its DNA, or some extra-chromosomal DNA necessary for its growth, characterized in that the bacterium comprises one or more genetic modifications which result in the thymidine biosynthetic pathway preferentially producing TdR at the expense of UdR as a consequence of one or more genetic modifications which increases the availability of a single carbon unit to dUMP for conversion to dTMP, wherein at least one genetic modification comprises introducing a transcriptional unit capable of expressing a dihydrofolate reductase (EC 1.5.1.3) and

wherein the bacterium comprises a host strain and at least one construct comprising extra-chromosomal DNA and wherein a host strain gene encoding a nucleoside diphosphate kinase (EC 2.7.4.6) of the bacterium has been knocked out or otherwise inactivated or excised.

2. The bacterium as claimed in claim 1 wherein the host strain is stabilized such that if the one or more constructs are lost, the host bacterium is unable to make DNA and dies.

3. The bacterium as claimed in claim 1 wherein the dihydrofolate reductase is a T even phage dihydrofolate reductase.

4. The bacterium as claimed in claim 3 wherein the T even phage is T4.

5. The bacterium as claimed in claim 1 wherein the transcriptional unit is a frd gene.

Assignments (2)
CHANGE OF ADDRESS Recorded Apr 16, 2025
From: GLAXO GROUP LIMITED
To: GLAXO GROUP LIMITED
Reel/Frame 071044/0904 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2008
From: COLLIS, ANDREW JOHN; PRESTON, CHRISTOPHER; ANDERSON, DAVID MARTIN; LIU, LIN; PODKOVYROV, SERGEY
To: GLAXO GROUP LIMITED
Reel/Frame 021340/0202 →
Priority Claims (1)
GB 0602339.4 · Feb 6, 2006 · national
Continuity (1)
Related Publication 20090081735A1 · Mar 26, 2009